{"product_id":"emergentbiosolutions-bcg-matrix","title":"Emergent BioSolutions Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where Emergent BioSolutions’ products land — Stars, Cash Cows, Dogs or Question Marks? This snapshot teases the positioning; the full BCG Matrix gives quadrant-by-quadrant clarity, data-driven recommendations, and a plug-and-play Word + Excel set you can use in meetings. Skip the guesswork—purchase the complete report to align investment and product moves with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrthopox portfolio (ACAM2000, Tembexa)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrthopox portfolio (ACAM2000, Tembexa) sits in Stars: Tembexa received FDA approval in 2021 and ACAM2000 has been licensed since 2007, positioning Emergent with scarce smallpox readiness assets. Geopolitics and government stockpile programs (Strategic National Stockpile) drive elevated demand and outsized awards to holders of licensed products. Continue investing in supply reliability and lifecycle upgrades to capture stockpile refresh cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOverdose reversal (NARCAN Nasal Spray)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMass-market awareness and sustained policy tailwinds (CDC provisional: \u0026gt;110,000 US overdose deaths in 2023) are driving rapid naloxone adoption; category growth remains high and Emergent stays a core scaled manufacturer of NARCAN Nasal Spray. Distribution is broadening from public health programs into retail and pharmacies. Double down on access, education, and co-pay support to defend share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnthrax medical countermeasures leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBetween vaccine and antitoxin, Emergent occupies a central role in anthrax medical countermeasures, supported by ongoing multi-year procurements and national readiness exercises that sustain rising production volumes.\u003c\/p\u003e\n\u003cp\u003eThe market continues to expand through modernization and stockpile replenishment, driving demand for both current formulations and next-generation candidates.\u003c\/p\u003e\n\u003cp\u003eContinued investment is required to lock in manufacturing capacity and advance improved formulations to meet evolving government requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment partnerships \u0026amp; BARDA anchor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrime vendor status with BARDA and sustained past performance create a durable moat for Emergent, concentrating biodefense wins as government budgets rise.\u003c\/p\u003e\n\u003cp\u003ePipeline funding plus recurring base awards sustain a revenue flywheel that rewards top partners; protect this with flawless delivery and transparent pricing to retain sole-source advantages.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrime vendor status\u003c\/li\u003e\n\u003cli\u003ePipeline + base awards\u003c\/li\u003e\n\u003cli\u003eFlawless delivery\u003c\/li\u003e\n\u003cli\u003eTransparent pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurge-ready biomanufacturing for countermeasures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSurge-ready biomanufacturing for countermeasures is mission-critical work, not generic CDMO services: Emergent scales validated cGMP facilities to respond to biological threats in weeks, leveraging \u0026gt;$1B annual revenue (2023) and high entry barriers from regulatory approvals. Growth spikes during emergencies; long-term federal contracts drive customer stickiness and rapid payoff when capacity is kept warm and audit-ready.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScale: validated surge in 4–8 weeks\u003c\/li\u003e\n\u003cli\u003eFinancial: \u0026gt;$1B revenue (2023)\u003c\/li\u003e\n\u003cli\u003eContracts: multi-year federal agreements\u003c\/li\u003e\n\u003cli\u003eOperational: maintain warm capacity and continuous audit-readiness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStockpile-driven therapies and overdose rescue: invest in capacity, delivery, refresh cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrthopox (Tembexa approved 2021; ACAM2000 licensed 2007) and naloxone (NARCAN) are Stars driven by government stockpiles and public-health demand; Emergent reported \u0026gt;$1B revenue (2023) and benefits from BARDA\/Strategic National Stockpile programs. Invest in capacity, lifecycle upgrades, access and delivery to capture refresh cycles and retail expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003e2023 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTembexa\/ACAM2000\u003c\/td\u003e\n\u003ctd\u003eLicensed\/Approved\u003c\/td\u003e\n\u003ctd\u003eStockpile awards\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNARCAN\u003c\/td\u003e\n\u003ctd\u003eMass adoption\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;110,000 OD deaths (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix for Emergent BioSolutions: assigns products to Stars, Cash Cows, Question Marks, Dogs with strategic invest\/hold\/divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix for Emergent BioSolutions — clarifies portfolio focus, eases exec decisions and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioThrax (anthrax vaccine) steady awards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioThrax benefits from large, predictable U.S. Strategic National Stockpile procurements that keep demand steady in this mature anthrax vaccine category. High market share, proven efficacy, and established manufacturing and regulatory processes support strong gross margins. Minimal promotional spend is needed because government procurement cadence drives sales. Focusing on yield improvements and lower COGS preserves ongoing cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBAT (botulism antitoxin heptavalent)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBAT (botulism antitoxin heptavalent) is a niche but essential biodefense product with limited competition, securing multi-year government procurements; as of 2024 these long-cycle contracts commonly span 3–5 years. Manufacturing know-how creates high barriers to entry, supporting durable revenue. Incremental process improvements flow almost directly to cash, boosting free cash generation per contract.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRSDL decontamination franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2024 RSDL remains standard issue for US DoD and select allied agencies, delivering predictable replacement cycles that underpin steady government procurement. The market is mature with few credible substitutes, driving low customer churn and reliable reorder behavior. Minimal marketing is required; management emphasis is on cost discipline and rolling out small-format extensions to capture supplemental field demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService revenue from validated facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eService revenue from validated facilities functions as a cash cow for Emergent: once a site is qualified, follow-on work runs efficiently and follow-on projects smooth utilization, supporting predictable margins. In 2024 Emergent leaned on recurring CDMO contracts that drove steady service margins as tight scheduling and tech-transfer know-how cut cycle times. The strategy is operationally conservative: keep the calendar full, not flashy.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003evalidated-sites: rapid follow-ons\u003c\/li\u003e\n\u003cli\u003eutilization: stable base-load projects\u003c\/li\u003e\n\u003cli\u003emargins: improve with tight scheduling\u003c\/li\u003e\n\u003cli\u003estrategy: full calendar over flashy bids (2024 focus)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational government reorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAllied nations refresh stockpiles at a measured clip, making international government reorders a steady cash cow for Emergent BioSolutions with lower growth but high predictability.\u003c\/p\u003e\n\u003cp\u003eContracts tend to renew based on demonstrated performance and quality; currency swings and tender timing create timing risk but not long-term demand volatility.\u003c\/p\u003e\n\u003cp\u003eMaintain strategic procurement relationships and prioritize bid discipline to avoid margin erosion when competing on price.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDependable revenue stream\u003c\/li\u003e\n\u003cli\u003eLow growth, high renewal probability\u003c\/li\u003e\n\u003cli\u003eOperational performance drives contract retention\u003c\/li\u003e\n\u003cli\u003eProtect margins through relationship and bid strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin biodefense contracts: predictable multi-year revenue; focus on yield and COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioThrax, BAT, RSDL and validated CDMO sites generated stable, high-margin government revenue in 2024; typical SNS and allied stockpile procurements keep demand predictable. BAT and many procurements run 3–5 year contract cycles. Focus remains on yield, COGS reduction and bid discipline to protect margins and renewals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 status\u003c\/th\u003e\n\u003cth\u003econtract len\u003c\/th\u003e\n\u003cth\u003erenewal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioThrax\u003c\/td\u003e\n\u003ctd\u003eSNS primary\u003c\/td\u003e\n\u003ctd\u003emulti-year\u003c\/td\u003e\n\u003ctd\u003ehigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBAT\u003c\/td\u003e\n\u003ctd\u003eniche biodefense\u003c\/td\u003e\n\u003ctd\u003e3–5 yrs\u003c\/td\u003e\n\u003ctd\u003ehigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eEmergent BioSolutions BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you’re previewing here is the exact BCG Matrix report you’ll receive after purchase. No watermarks, no demo text—just a fully formatted, analysis-ready document crafted for clarity and decision-making. Once bought it’s delivered straight to your inbox and is immediately editable, printable, and presentation-ready. No surprises—just a one-time purchase for a professional strategic tool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163488006521,"sku":"emergentbiosolutions-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/emergentbiosolutions-bcg-matrix.png?v=1762721059","url":"https:\/\/portersfiveforce.com\/products\/emergentbiosolutions-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}